Effect of glucagon-like peptide 1 receptor agonist medications on weight loss in patients with and without polycystic ovary syndrome
- PMID: 40239888
- DOI: 10.1016/j.fertnstert.2025.04.009
Effect of glucagon-like peptide 1 receptor agonist medications on weight loss in patients with and without polycystic ovary syndrome
Conflict of interest statement
Declaration of Interests E.G. has nothing to disclose. L.L. has nothing to disclose. I.T.L. has nothing to disclose. N.K. has nothing to disclose. A.A. reports funding and consulting fees from Novo Nordisk, outside the submitted work. A.D. reports funding from the National Institutes of Health, Patient-Centered Outcomes Research Institute, Independence Blue Cross, and Ferring and consulting fees from May Health and Ferring, outside the submitted work.
LinkOut - more resources
Full Text Sources